35
Participants
Start Date
May 24, 2018
Primary Completion Date
May 9, 2025
Study Completion Date
May 9, 2025
INO-5401
INO-5401 (9 milligram \[mg\] dose IM): mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen.
INO-9012
"INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).~INO-5401 + INO-9012 will be administered IM followed by EP with CELLECTRA™ 2000 device every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator."
Atezolizumab
Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.
CELLECTRA™ 2000
IM injection of INO-5401 and INO-9012 is followed by EP with the CELLECTRA™ 2000 device.
New York University Langone Medical Center - Perlmutter Cancer Center, New York
Columbia University, Herbert Irving Comprehensive Cancer Center, New York
University of Pittsburgh Medical Center, Pittsburgh
Johns Hopkins University School of Medicine, Baltimore
Inova Melanoma and Skin Cancer Center, Fairfax
University of North Carolina School of Medicine, Chapel Hill
Greenville Memorial Hospital, Greenville
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa
Karmanos Cancer Institute, Detroit
Washington University School of Medicine in St. Louis, St Louis
Mayo Clinic Cancer Center, Phoenix
Lead Sponsor
Inovio Pharmaceuticals
INDUSTRY